mitoxantrone and African Lymphoma
mitoxantrone has been researched along with African Lymphoma in 7 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Histopathological subtypes consist of Burkitt's lymphoma (BL) in 32 (43." | 1.48 | Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan. ( Anwar, S; Faizan, M; Khan, S, 2018) |
Research
Studies (7)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (28.57) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Witiak, DT | 1 |
Kamat, PL | 1 |
Allison, DL | 1 |
Liebowitz, SM | 1 |
Glaser, R | 1 |
Holliday, JE | 1 |
Moeschberger, ML | 1 |
Schaller, JP | 1 |
Faizan, M | 1 |
Anwar, S | 1 |
Khan, S | 1 |
Plasschaert, SL | 1 |
van der Kolk, DM | 1 |
de Bont, ES | 1 |
Kamps, WA | 1 |
Morisaki, K | 1 |
Bates, SE | 1 |
Scheffer, GL | 1 |
Scheper, RJ | 1 |
Vellenga, E | 1 |
de Vries, EG | 1 |
Mantzios, G | 1 |
Tsirigotis, P | 1 |
Veliou, F | 1 |
Boutsikakis, I | 1 |
Petraki, L | 1 |
Kolovos, J | 1 |
Papageorgiou, S | 1 |
Robos, Y | 1 |
van Imhoff, GW | 1 |
van der Holt, B | 1 |
MacKenzie, MA | 1 |
Ossenkoppele, GJ | 1 |
Wijermans, PW | 1 |
Kramer, MH | 1 |
van 't Veer, MB | 1 |
Schouten, HC | 1 |
van Marwijk Kooy, M | 1 |
van Oers, MH | 1 |
Raemaekers, JM | 1 |
Sonneveld, P | 1 |
Meulendijks, LA | 1 |
Kluin, PM | 1 |
Kluin-Nelemans, HC | 1 |
Verdonck, LF | 1 |
Chow, KU | 1 |
Sommerlad, WD | 1 |
Boehrer, S | 1 |
Schneider, B | 1 |
Seipelt, G | 1 |
Rummel, MJ | 1 |
Hoelzer, D | 1 |
Mitrou, PS | 1 |
Weidmann, E | 1 |
Ohnuma, T | 1 |
Arkin, H | 1 |
Holland, JF | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352] | Phase 2 | 22 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Duration of Response
Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months
Intervention | months (Median) |
---|---|
Bendamustine/Ofatumumab | 5.6 |
Number of Patients With a Complete Response
Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months
Intervention | Participants (Count of Participants) |
---|---|
Bendamustine/Ofatumumab | 7 |
Number of Patients With Treatment-Related Adverse Events (AEs) as a Measure of Safety
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks
Intervention | Participants (Count of Participants) |
---|---|
Bendamustine/Ofatumumab | 16 |
Overall Response (OR)
Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months
Intervention | Participants (Count of Participants) |
---|---|
Bendamustine/Ofatumumab | 19 |
Overall Survival (OS)
Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months
Intervention | months (Median) |
---|---|
Bendamustine/Ofatumumab | 12.0 |
Progression-free Survival
Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
Intervention | months (Median) |
---|---|
Bendamustine/Ofatumumab | 8.6 |
Time to Progression (TTP)
Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
Intervention | months (Median) |
---|---|
Bendamustine/Ofatumumab | 10.5 |
Reviews
1 review available for mitoxantrone and African Lymphoma
Article | Year |
---|---|
Primary adrenal lymphoma presenting as Addison's disease: case report and review of the literature.
Topics: Addison Disease; Adrenal Cortex Neoplasms; Aged; Aged, 80 and over; Antineoplastic Combined Chemothe | 2004 |
Trials
1 trial available for mitoxantrone and African Lymphoma
Article | Year |
---|---|
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2005 |
Other Studies
5 other studies available for mitoxantrone and African Lymphoma
Article | Year |
---|---|
Bis(bioreductive) alkylating agents: synthesis and biological activity in a nude mouse human carcinoma model.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Burkitt Lymphoma; Cell Line; Cisplatin; Drug Resistan | 1983 |
Demographics and Outome in Paediatric Non-Hodgkin Lymphoma: Single Centre Experience at The Children Hospital Lahore, Pakistan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2018 |
The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transpo | 2003 |
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Der | 2002 |
Effects of cell density on drug-induced cell kill kinetics in vitro (inoculum effect).
Topics: Antineoplastic Agents; Bleomycin; Burkitt Lymphoma; Carboplatin; Cell Count; Cell Survival; Cisplati | 1986 |